Trial reportScientific reports2026
Efficacy of oral azithromycin versus oral doxycycline in treating moderate acne vulgaris and their effects on patients' quality of life.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to compare the efficacy of oral azithromycin with oral doxycycline in moderate acne vulgaris and to assess the corresponding changes in patient-reported quality-of-life. In this open label, randomised controlled trial conducted at a university student clinic, Muscat, Oman, 163 patients with moderate and severe acne vulgaris were assigned equally to receive either oral azithromycin or oral doxycycline. Treatments were administered over a three-month period with monthly clinical assessments. Acne severity was quantified using a validated acne severity scale, and quality of life was measured at baseline and at study end via a standardised questionnaire. Analyses were performed using univariate statistics. The cohort comprised 163 participants (mean age 20.2 ± 1.7 years; 67.3% female). Both groups experienced significant and comparable reductions in acne severity after three months. Parallel, statistically significant improvements were observed in quality-of-life scores across domains related to symptoms, emotional well-being, and social functioning. Oral azithromycin and doxycycline demonstrate equivalent efficacy in reducing moderate acne vulgaris and both confer substantial enhancements in patients' quality of life. These findings support either antibiotic as an appropriate option for addressing both the dermatological and psychosocial burdens of moderate acne. The trial was registered with the Australia New Zealand Clinical Trial Registry (ACTRN12619000073101; Date: 18
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.